Key Takeaways
- Self-collected vaginal swabs tested by NAAT perform close to clinician-collected specimens. In a 2015 PLOS ONE meta-analysis (Lunny et al.), self-collected vaginal swabs had a pooled sensitivity of 92% and specificity of 98% for chlamydia; vaginal-swab data for gonorrhea came from a single study.[2]
- Dried blood spot (DBS) testing has published support, but performance varies by infection. A 2017 PLOS ONE study comparing DBS with venous blood found 100% sensitivity for HIV, but 93% for syphilis and 90% for hepatitis B surface antigen, with specificity of 99% or higher.[9]
- Home-based STI testing increases screening uptake: a 2010 Obstetrics & Gynecology RCT by Graseck et al. found 56.3% of women completed screening in the home-collection arm versus 25.0% in the clinic arm, and a 2019 BMJ Global Health meta-analysis found that self-collection increased both testing uptake and case finding.[5][6]
- The Everlywell female panel screens for chlamydia, gonorrhea, hepatitis C, trichomonas, and syphilis; HIV inclusion depends on panel variant. The urine-based CT/NG test covers only chlamydia and gonorrhea. The Visby rapid PCR, which Everlywell also sells, is a separate product for immediate point-of-care testing.
- A positive result requires clinician follow-up for confirmatory testing where indicated, treatment per CDC 2021 STI guidelines, and partner notification. This is not a step to skip.[7]
What This Test Is
The Everlywell STI Test Panel belongs to a category of at-home testing that has been studied since at least the mid-2000s, when an internet-based program mailed self-collection kits for chlamydia and gonorrhea screening[4]: mail-in, lab-processed kits where the user collects specimens at home and ships them to a CLIA-certified laboratory for analysis. This model differs in a practical and technically meaningful way from the Visby Women's Sexual Health Test, which uses an FDA-authorized at-home PCR device to process samples locally and return results in approximately 30 minutes.
The Everlywell female finger-prick panel screens for five infections: Chlamydia trachomatis, Neisseria gonorrhoeae, hepatitis C virus (HCV), Trichomonas vaginalis, and syphilis. Collection uses two methods: a vaginal swab for NAAT-based detection of chlamydia, gonorrhea, and trichomonas; and a finger-prick dried blood spot (DBS) card for serological testing of HCV and syphilis. Some panel configurations also include HIV antibody testing via DBS. Separately, Everlywell offers a urine-based CT/NG NAAT that covers only chlamydia and gonorrhea.
Everlywell also sells the Visby Women's Sexual Health Test, the rapid PCR device. These are distinct products. The Visby rapid test returns results the same day; the mail-in Everlywell panel requires several days for lab processing and result delivery. Coverage differs too: Visby covers three infections; the Everlywell mail-in panel covers five (or more, depending on variant).
The USPSTF recommends chlamydia and gonorrhea screening for all sexually active women 24 years or younger, and for women 25 or older who are at increased risk.[1] The USPSTF notes that screening intervals have not been studied; CDC recommends annual chlamydia screening for all sexually active women younger than 25, as well as screening of older women at increased risk.[7] Mail-in testing offers one pathway to meet that recommendation for people who find clinic visits logistically difficult or prefer the privacy of home collection.
The Evidence
Self-Collected Vaginal Swabs for NAAT
The most important accuracy question for the Everlywell swab component is whether self-collected specimens perform as well as clinician-collected ones. The evidence on this point is consistent and favorable.
Lunny et al. published a systematic review and meta-analysis in PLOS ONE in 2015 that included 21 studies with over 6,100 paired samples comparing self-collected specimens with clinician-collected specimens for C. trachomatis and N. gonorrhoeae detection by NAAT.[2] In six chlamydia studies comparing self-collected vaginal swabs with clinician-collected cervical swabs, pooled sensitivity was 92% (95% CI 87% to 95%) and specificity was 98%. For gonorrhea, only one study (309 women) compared self-collected vaginal swabs with clinician-collected cervical swabs; it reported sensitivity of 98% and specificity of 97%. The authors concluded that these results support the vaginal swab as the specimen of choice in home-based screening for chlamydia and gonorrhea. The USPSTF review reached a similar conclusion, finding that sensitivity varied little across vaginal clinician-collected, vaginal self-collected and urine specimens.[1]
The mail-in component adds a practical question: does specimen quality degrade when swabs are shipped to a central laboratory rather than processed immediately? Masek et al. addressed this directly in the Journal of Clinical Microbiology, examining NAAT performance on 1,000 self-collected vaginal swabs from an internet-based screening program, shipped dry.[4] With a reference standard of two or more positive NAATs, the Aptima Combo 2 assay detected chlamydia and gonorrhea with 100% sensitivity and 100% specificity, while the ProbeTec assay missed some infections (sensitivity 81.5% for chlamydia and 80% for gonorrhea). The authors concluded that NAATs perform well with self-obtained vaginal swabs shipped dry to a laboratory, though the result depends on the assay the laboratory uses.
Dried Blood Spot for Syphilis, HIV, and Hepatitis C
The DBS component of the Everlywell finger-prick panel covers serology: antibody detection for infections that require a blood sample. The evidence here is real but more variable than for swabs, and published reviews note uneven study quality.[10]
A 2017 PLOS ONE study by van Loo et al. examined DBS for HIV, hepatitis B surface antigen (HBsAg), and syphilis screening in 217 participants, mostly men who have sex with men at a Dutch STI clinic, comparing DBS results with blood drawn from a vein.[9] For HIV (195 pairs), DBS sensitivity and specificity were 100%. For syphilis (191 pairs), sensitivity was 93% with specificity of 99%. For HBsAg (202 pairs), sensitivity was 90% with specificity of 99%. In 91% of DBS cards, enough blood was collected to run all three tests. The authors concluded that DBS is a valid alternative to venous blood draw, but the lower syphilis sensitivity means a negative DBS syphilis result can still miss some infections.
For hepatitis C specifically, a 2019 systematic review and meta-analysis in Scientific Reports by Vázquez-Morón et al. pooled 21 studies of anti-HCV antibody detection on DBS.[8] Pooled sensitivity was 96.1% and pooled specificity was 99.2%. The authors noted publication bias and significant heterogeneity between studies, and found a low positive predictive value when HCV prevalence was under 10%. A 2024 narrative systematic review in PLOS Global Public Health by Cholette et al. found sensitivity of 90% or higher in 62.5% of reported DBS sensitivity measurements and specificity of 90% or higher in 84.9%, but study quality varied greatly, and the authors concluded that validity depends on thorough method development and validation.[10]
Does Home-Based Testing Increase Uptake?
Performance data matter only if people actually use the test. Several studies address whether home-based STI screening achieves better population coverage than clinic-based screening.
Graseck et al. conducted an RCT among 558 women using long-acting reversible contraception, comparing home-based chlamydia and gonorrhea screening to clinic-based screening.[5] By tests received or documented in medical records, 56.3% of women in the home arm completed screening versus 25.0% in the clinic arm (relative risk 2.2). A 2019 meta-analysis published in BMJ Global Health pooled 11 studies from Australia, Denmark and the USA and found that programs offering self-collection increased STI testing uptake (relative risk 2.94) and case finding (relative risk 2.17).[6] Not every review is as positive: a 2015 Cochrane review by Fajardo-Bernal et al. found that gains in the share of people tested with home collection were offset by a lower share of positive results, and evidence on whether home collection improved the number of people tested, diagnosed and treated was inconclusive.[3]
Evidence Comparison Table
The table below summarizes published sensitivity and specificity data for the specimen types and infection targets used in the Everlywell mail-in panel, drawn from peer-reviewed sources.
| Specimen / Infection | Method | Sensitivity | Specificity | Source |
|---|---|---|---|---|
| Self-collected vaginal swab / C. trachomatis | NAAT (6 studies pooled) | 92% | 98% | Lunny et al., PLOS ONE 2015[2] |
| Self-collected vaginal swab / N. gonorrhoeae | NAAT (1 study, 309 women) | 98% | 97% | Lunny et al., PLOS ONE 2015[2] |
| DBS finger-prick / HIV | HIV serological screening assay on DBS (195 pairs) | 100% | 100% | van Loo et al., PLOS ONE 2017[9] |
| DBS finger-prick / Syphilis (treponemal) | Treponemal antibody assay on DBS (191 pairs) | 93% | 99% | van Loo et al., PLOS ONE 2017[9] |
| DBS finger-prick / Hepatitis C (anti-HCV) | Anti-HCV antibody assays on DBS (21 studies pooled) | 96.1% (pooled) | 99.2% (pooled) | Vázquez-Morón et al., Sci Rep 2019[8] |
| Patient- or clinician-collected vaginal swab, or urine / T. vaginalis | FDA-cleared NAAT (one assay; range across specimen types) | 96.2% to 100% | 99.1% to 100% | CDC 2021 STI Treatment Guidelines[7] |
Buyer's Guide
What's in the Kit
The Everlywell female STI panel includes collection materials for two specimen types. The NAAT component uses a vaginal self-swab that is sealed in a specimen bag and placed in the prepaid return mailer. The DBS component uses a finger-prick lancet and a collection card; you apply several drops of blood to the card, allow it to dry fully, then include it in the same return package. Detailed collection instructions are included, and the Everlywell app provides a step-by-step collection guide.
How Collection Works
Vaginal swab collection is done by following the kit's written instructions, and no clinician assistance is required. In the studies summarized above, self-collected vaginal swabs performed close to clinician-collected cervical swabs.[2]
The DBS finger-prick is simple but technique-sensitive. The most common collection error is insufficient blood volume or smearing rather than dropping blood onto the collection circles. The card must be dried fully, as the kit instructions direct, before packaging. In the van Loo study, 91% of DBS cards had enough blood to run all three tests, so a share of cards can fall short.[9]
Turnaround Time
After the lab receives the specimen, processing and result delivery typically occurs within several business days. Everlywell notes turnaround "in days" on its product page. That reflects lab processing time plus notification to the app, not total time from collection, so add shipping time when estimating when you'll receive a result. This is a meaningful difference from the Visby rapid PCR: if time is urgent, the mail-in model has inherent delays.
Who This Panel Screens
The female finger-prick panel is designed for people with female anatomy. The urine-based CT/NG variant accepts urine samples and may be used by anyone; confirm the specific panel's collection instructions before ordering. The panel is not a substitute for a pelvic exam and does not screen for HPV, herpes simplex virus (HSV), or bacterial vaginosis.
What's Not Included
- HIV: Included in some Everlywell panel configurations via DBS antibody testing; not present in the urine-only CT/NG test. Confirm panel contents when ordering.
- HPV and HSV: Neither is included in the Everlywell STI panel. For a genital sore, CDC describes HSV NAAT testing of the lesion as the most sensitive test, which requires an in-person visit.[7]
- Hepatitis B: Not currently part of the standard Everlywell STI panel.
- Physical examination: The kit cannot assess for signs of pelvic inflammatory disease, cervical motion tenderness, lymphadenopathy, or ulcerative lesions. These findings require in-person evaluation.
Price Range
Everlywell's STI panels are generally priced in the range of the broader mail-in testing market for comparable panel coverage. Pricing changes, and specific figures on the product page should be verified directly before ordering; this review does not quote a specific price to avoid stating an outdated number. Insurance coverage is not standard for at-home STI panels from consumer testing companies, though HSA and FSA eligibility may apply. Some panels are available through employer wellness programs or telehealth partnerships at reduced cost.
Reading Your Result
What "Detected" Means
A positive (detected) result for a NAAT-based target means the laboratory identified genetic material from the pathogen in your specimen. For DBS-based targets, a reactive result means the laboratory detected antibodies consistent with prior or current infection. Specificity was high in the studies above, but when an infection is uncommon among the people tested, a meaningful share of positive results can still be false: the hepatitis C DBS meta-analysis found a low positive predictive value when prevalence was under 10%.[8] Neither type of result is a final clinical diagnosis on its own.
Confirmatory testing is standard practice for certain pathogens. CDC's 2021 STI Treatment Guidelines state that a single type of syphilis blood test is not enough for diagnosis, and that a positive treponemal screening test should be followed by a quantitative nontreponemal test (such as RPR) with a titer to guide management.[7] A preliminary positive HIV screening test should be followed by supplemental testing to establish the diagnosis.[7] Your clinician handles this step.
What "Not Detected" Means, and What It Doesn't Mean
A negative result means the targeted pathogens were not detected in the collected specimen. Several important caveats apply.
Window periods matter. According to CDC, antibody tests can usually detect HIV 23 to 90 days after exposure, and an antigen/antibody lab test on blood from a vein can usually detect HIV 18 to 45 days after exposure; no HIV test can detect HIV immediately after infection.[11] Syphilis blood tests can also miss early infection: CDC notes that relying on one type of syphilis test can give false-negative results in people tested during primary syphilis.[7] Testing too soon after a potential exposure can produce a false-negative result. If there is a recent exposure concern, CDC advises retesting after the window period for the test used has passed.[11]
The panel does not test for everything. A negative Everlywell STI result does not provide reassurance about HPV, HSV, bacterial vaginosis, or hepatitis B. If those infections are a concern, separate testing is needed.
Collection quality also matters. An inadequate vaginal swab specimen or an incompletely dried DBS card can produce a false-negative result. If symptoms persist after a negative result, see a clinician rather than assuming the test has definitively cleared you.
Next Steps After a Positive Result
A positive STI panel result does not mean you treat yourself. What it means is that you now have actionable clinical information and need to bring it to a clinician who can confirm the result where indicated, prescribe appropriate treatment, and coordinate partner notification. Two paths accomplish this, and neither is superior; they serve different circumstances.
Telehealth Visit
- Same-day or next-day access with a board-certified physician via secure video or messaging
- Clinician reviews your result, takes a history, and assesses for red flags
- E-prescriptions sent directly to your pharmacy for oral treatments
- Appropriate for chlamydia (CDC 2021 recommended regimen outside pregnancy: doxycycline 100 mg twice daily for 7 days) and trichomonas (oral metronidazole; for women, 500 mg twice daily for 7 days)[7]
- For syphilis, the telehealth clinician reviews titer results and stage, and can coordinate in-person penicillin injection if indicated; CDC states that parenteral penicillin G is the preferred treatment for all stages of syphilis[7]
- Lab orders for confirmatory testing (e.g., syphilis reflex, HIV differentiation, HCV RNA) can be placed remotely and drawn at a nearby lab
In-Person Care
- Primary care physician, urgent care, or sexual health clinic
- Needed for gonorrhea treatment in most cases: CDC's recommended regimen is a single ceftriaxone 500 mg intramuscular injection (1 g for people weighing 150 kg or more), which has to be given in person. CDC lists alternatives only for when ceftriaxone is not available, and a clinician decides whether one applies[7]
- Needed for penicillin injections used to treat syphilis[7]
- Planned Parenthood and local health departments often provide sliding-scale fees for STI treatment
- Allows same-visit pelvic exam if abnormal bleeding, discharge, or pelvic pain is present
- Preferable when symptoms suggest pelvic inflammatory disease or systemic involvement
Regardless of which path is chosen: notify recent sexual partners so they can be tested and treated. CDC guidelines cover partners from the past 60 days for chlamydia and gonorrhea. For syphilis the window depends on stage: 3 months plus the duration of symptoms for primary syphilis, 6 months plus the duration of symptoms for secondary syphilis, and 1 year for early latent syphilis.[7] CDC also recommends retesting about 3 months after treatment for chlamydia and gonorrhea, because many repeat infections come from untreated partners or new partners.[7]
When the Test Is Not Enough
Mail-in STI testing fills an important gap in access, but it has clear limits. Some clinical situations require in-person evaluation regardless of what a home test shows, or instead of one.
Seek In-Person Care If:
- You have fever or pelvic or lower abdominal pain: these can indicate pelvic inflammatory disease, which CDC describes as diagnosed partly on findings from a pelvic examination[7]
- You have visible genital ulcers or sores: in the United States most are caused by genital herpes or syphilis, and the sore itself needs in-person evaluation and testing[7]
- You are pregnant or may be pregnant: STI screening and treatment in pregnancy follow specific CDC recommendations and need involvement of the clinician managing the pregnancy[7]
- You have abnormal vaginal bleeding not otherwise explained
- Symptoms persist or worsen after a negative home test result
- You have been sexually assaulted: CDC advises that the examination be done by an experienced clinician in a way that minimizes further trauma, so go to an emergency department or a sexual assault program rather than relying on a home kit[7]
Expedited partner therapy (EPT), which provides treatment to a partner without that partner being examined, is a useful adjunct to home-based testing, but its availability depends on state law. CDC notes that EPT is legal in the majority of states but varies by infection (chlamydia or gonorrhea).[7] Your clinician can advise on what is legally available in your state.
Pregnancy-specific considerations apply at several steps. CDC recommends that all pregnant women be screened for syphilis at the first prenatal visit, even if they have been tested before. For chlamydia in pregnancy, CDC states that azithromycin is safe and effective, while doxycycline is contraindicated in the second and third trimesters; pregnant women treated for chlamydia also need a test of cure about 4 weeks after treatment and retesting at 3 months.[7] Any positive STI result during pregnancy should go promptly to the clinician managing the pregnancy rather than waiting for a telehealth slot.
Bottom Line
The evidence for the Everlywell STI panel's two core technologies, self-collected NAAT swabs and DBS serology, is real but uneven. Self-collected vaginal swabs perform close to clinician-collected specimens for chlamydia, with less data for gonorrhea.[2] DBS antibody testing performed well for HIV and hepatitis C in the studies reviewed here, but DBS syphilis sensitivity was 93% in one study and DBS study quality varies.[8][9][10] Offering home collection increases testing uptake, though one Cochrane review found the gain in people tested was offset by a lower share of positive results.[3][5][6]
The limitations are real. Turnaround takes days, not minutes, a meaningful distinction from the Visby rapid PCR. Window periods apply to all serological targets. The panel does not cover HPV, herpes, or bacterial vaginosis. A positive result is not a self-treatment prompt.
Used as a screening tool by someone without acute symptoms, the Everlywell mail-in panel has a defensible evidence base. Used well, it should end at a clinician, by telehealth or in person, who can confirm results, prescribe the right treatment, and ensure partners are addressed.
Frequently Asked Questions
How accurate is the Everlywell STI panel for chlamydia and gonorrhea?
Research on self-collected vaginal swabs tested by NAAT shows performance close to clinician-collected specimens. A 2015 PLOS ONE meta-analysis by Lunny et al. found pooled sensitivity of 92% and specificity of 98% for C. trachomatis with self-collected vaginal swabs; for N. gonorrhoeae, a single study reported sensitivity of 98% and specificity of 97%.[2] Masek et al. found that self-collected vaginal swabs shipped dry to a laboratory performed well, with 100% sensitivity and specificity on the Aptima Combo 2 assay, though another assay missed some infections.[4]
Does the Everlywell STI panel test for HIV?
HIV inclusion depends on the specific panel variant ordered. The female finger-prick panel includes HIV antibody testing via DBS in some configurations. The urine-only CT/NG NAAT does not include HIV. The Visby rapid PCR, which Everlywell also sells, does not include HIV. Confirm panel contents when ordering if HIV screening is a priority.
What should you do after a positive Everlywell result?
Contact a clinician, by telehealth or in person, for confirmatory testing where indicated, treatment per CDC 2021 STI guidelines, and partner notification.[7] Chlamydia and trichomonas can usually be managed via telehealth with oral prescriptions. CDC's recommended gonorrhea treatment is a single ceftriaxone 500 mg intramuscular injection (1 g for people weighing 150 kg or more), which is given in person. Syphilis treatment depends on stage. Do not self-treat with leftover antibiotics.
How is the Everlywell mail-in panel different from the Visby at-home PCR test?
The Everlywell mail-in panel ships specimens to a certified laboratory, returning results in several days via app. The Visby Women's Sexual Health Test is an FDA-authorized device that runs PCR locally and returns results in approximately 30 minutes. Everlywell covers more pathogens (including syphilis, hepatitis C, and in some variants HIV); Visby covers only chlamydia, gonorrhea, and trichomoniasis but offers a same-day result.
References
- U.S. Preventive Services Task Force. "Chlamydia and Gonorrhea: Screening." Final recommendation statement, September 14, 2021. Accessed November 7, 2026. uspreventiveservicestaskforce.org
- Lunny C, Taylor D, Hoang L, et al. "Self-Collected versus Clinician-Collected Sampling for Chlamydia and Gonorrhea Screening: A Systemic Review and Meta-Analysis." PLoS One. 2015;10(7):e0132776. journals.plos.org
- Fajardo-Bernal L, Aponte-Gonzalez J, Vigil P, et al. "Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae infections." Cochrane Database Syst Rev. 2015;2015(9):CD011317. pmc.ncbi.nlm.nih.gov
- Masek BJ, et al. "Performance of Three Nucleic Acid Amplification Tests for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by Use of Self-Collected Vaginal Swabs Obtained via an Internet-Based Screening Program." J Clin Microbiol. 2009;47(6):1663-1667. pmc.ncbi.nlm.nih.gov
- Graseck AS, Secura GM, Allsworth JE, et al. "Home compared with clinic-based screening for sexually transmitted infections: a randomized controlled trial." Obstet Gynecol. 2010;116(6):1311-1318. pmc.ncbi.nlm.nih.gov
- Ogale Y, Yeh PT, Kennedy CE, et al. "Self-collection of samples as an additional approach to deliver testing services for sexually transmitted infections: a systematic review and meta-analysis." BMJ Glob Health. 2019;4(2):e001349. pmc.ncbi.nlm.nih.gov
- Workowski KA, Bachmann LH, Chan PA, et al. (Centers for Disease Control and Prevention). "Sexually Transmitted Infections Treatment Guidelines, 2021." MMWR Recomm Rep. 2021;70(4):1-187. pmc.ncbi.nlm.nih.gov
- Vázquez-Morón S, Ardizone Jiménez B, Jiménez-Sousa MA, et al. "Evaluation of the diagnostic accuracy of laboratory-based screening for hepatitis C in dried blood spot samples: A systematic review and meta-analysis." Sci Rep. 2019;9(1):7316. nature.com
- van Loo IHM, Dukers-Muijrers NHTM, Heuts R, et al. "Screening for HIV, hepatitis B and syphilis on dried blood spots: A promising method to better reach hidden high-risk populations with self-collected sampling." PLoS One. 2017;12(10):e0186722. journals.plos.org
- Cholette F, Périnet S, Neufeld B, et al. "Validity of dried blood spot testing for sexually transmitted and blood-borne infections: A narrative systematic review." PLOS Glob Public Health. 2024;4(6):e0003320. pmc.ncbi.nlm.nih.gov
- Centers for Disease Control and Prevention. "Getting Tested for HIV." Reviewed and updated September 15, 2026. Accessed November 7, 2026. cdc.gov